CytoDyn (CYDY) Stock Price, News & Analysis

Company Overview

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Key Stats

• Today's Range: $0.12 to $0.14
• 50-Day Range: $0.12 to $0.17
• 52-Week Range: $0.11 to $0.42
• Volume: 4.99 million shs
• Average Volume: 2.60 million shs
• Market Capitalization: $149.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CytoDyn Stock Analysis - MarketRank™

CytoDyn scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for CytoDyn.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CytoDyn is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CytoDyn is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.08% of the outstanding shares of CytoDyn have been sold short.

Short Interest Ratio / Days to Cover

CytoDyn has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CytoDyn has recently increased by 0.35%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CytoDyn does not currently pay a dividend.

Dividend Growth

CytoDyn does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.08% of the outstanding shares of CytoDyn have been sold short.

Short Interest Ratio / Days to Cover

CytoDyn has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CytoDyn has recently increased by 0.35%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for CytoDyn this week, compared to 0 articles on an average week.

Search Interest

Only 2 people have searched for CYDY on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

2 people have added CytoDyn to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CytoDyn insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.54% of the stock of CytoDyn is held by insiders.

Percentage Held by Institutions

Only 5.06% of the stock of CytoDyn is held by institutions.

CYDY Stock Analysis - Frequently Asked Questions

How have CYDY shares performed this year?

CytoDyn's stock was trading at $0.1950 at the beginning of the year. Since then, CYDY shares have decreased by 36.9% and is now trading at $0.1230.
View the best growth stocks for 2024 here.

How were CytoDyn's earnings last quarter?

CytoDyn Inc. (OTCMKTS:CYDY) released its quarterly earnings data on Tuesday, October, 15th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter.

How do I buy shares of CytoDyn?

Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of CytoDyn own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CytoDyn investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 10/15/2024
• Today: 11/04/2024
• Fiscal Year End: 5/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CYDY
• Previous Symbol: NASDAQ:CYDY
• CUSIP: 23283M101
• CIK: 1175680
• Web: www.cytodyn.com
• Phone: (360) 980-8524
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-49,840,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -129.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.40
• Quick Ratio: 0.40

Sales & Book Value

• Annual Sales: $270,000.00
• Price / Sales: 555.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -1.76

Miscellaneous

• Outstanding Shares: 1,219,350,000
• Free Float: 1,212,763,000
• Market Cap: $149.98 million
• Optionable: Not Optionable
• Beta: 0.17